From: Significance of mesothelin and CA125 expression in endometrial carcinoma: a retrospective analysis
Variables | Â | Univariate analysis | Multivariate analysis for mesothelin expression | Multivariate analysis for co-expression of mesothelin and CA125 | ||||||
---|---|---|---|---|---|---|---|---|---|---|
HR | (95% CI) | p-value | HR | (95% CI) | p-value | HR | (95% CI) | p-value | ||
Age | ≥ 60 vs. <  60 | 2.18 | (1.50–3.23) | < 0.01 | 1.79 | (1.19–2.72) | < 0.01 | 1.79 | (1.19–2.73) | < 0.01 |
Histological type | Grade 2 endometrioid carcinoma vs. Grade 1 endometrioid carcinoma | 3.37 | (1.95–5.96) | < 0.01 | 2.01 | (1.12–3.67) | 0.019 | 2.02 | (1.12–3.69) | 0.018 |
 | Grade 3 endometrioid carcinoma vs. Grade 1 endometrioid carcinoma | 5.17 | (2.88–9.36) | < 0.01 | 2.83 | (1.49–5.42) | < 0.01 | 2.84 | (1.50–5.45) | < 0.01 |
 | Other carcinomas vs. Grade 1 endometrioid carcinoma | 8.92 | (4.41–12.6) | < 0.01 | 2.48 | (1.34–4.70) | < 0.01 | 2.49 | (1.35–4.72) | < 0.01 |
FIGO stage | III. IV vs. I. II | 7.82 | (5.42–11.4) | < 0.01 | 2.07 | (1.08–3.94) | 0.028 | 2.07 | (1.07–3.93) | 0.029 |
Depth of myometrial invasion | ≥1/2 vs. < 1/2 | 3.84 | (2.66–5.60) | < 0.01 | 1.59 | (0.99–2.58) | 0.054 | 1.57 | (0.97–2.55) | 0.061 |
Lymphovascular invasion | Yes vs. No | 3.84 | (2.62–5.75) | < 0.01 | 1.94 | (1.16–3.25) | 0.01 | 1.94 | (1.17–3.25) | 0.01 |
Cervical invasion | Yes vs. No | 2.23 | (1.50–3.25) | < 0.01 | 1.44 | (0.92–2.24) | 0.10 | 1.45 | (0.92–2.45) | 0.10 |
Ovarian metastasis | Yes vs. No | 7.48 | (4.68–11.5) | < 0.01 | 1.21 | (0.67–2.13) | 0.51 | 1.21 | (0.67–2.14) | 0.50 |
Lymph node metastasis | Yes vs. No | 5.64 | (3.68–8.58) | < 0.01 | 1.26 | (0.70–2.31) | 0.44 | 1.25 | (0.69–2.30) | 0.45 |
 | Yes vs. Unevaluated | 1.94 | (1.20–3.14) | < 0.01 | 1.27 | (0.71–2.31) | 0.41 | 1.27 | (0.70–2.31) | 0.41 |
 | Unevaluated vs. No | 2.91 | (1.84–4.51) | < 0.01 | 0.96 | (0.57–1.68) | 0.96 | 0.98 | (0.57–1.67) | 0.96 |
Distant metastasis | Yes vs. No | 12.5 | (8.14–18.9) | < 0.01 | 5.89 | (3.11–11.1) | < 0.01 | 5.87 | (3.10–11.1) | < 0.01 |
Peritoneal cytology | Positive vs. Negative | 4.42 | (3.04–6.38) | < 0.01 | 1.59 | (0.98–2.58) | 0.058 | 1.59 | (0.97–2.57) | 0.06 |
Adjuvant therapy | Yes vs. No | 2.55 | (1.71–3.89) | < 0.01 | 0.45 | (0.26–0.78) | < 0.01 | 0.45 | (0.26–0.78) | < 0.01 |
Mesothelin expression | Yes vs. No | 2.74 | (1.91–3.94) | < 0.01 | 2.14 | (1.45–3.16) | < 0.01 |  |  |  |
CA125 expression | Yes vs. No | 1.01 | (0.68–1.56) | 0.92 |  |  |  |  |  |  |
Co-expression of mesothelin and CA125 | Yes vs. No | 2.86 | (2.00–4.12) | < 0.01 |  |  |  | 2.19 | (1.49–3.23) | < 0.01 |